(NASDAQ: STLN) Starling Oncology's forecast annual revenue growth rate of 20.91% is forecast to beat the US Medical Care Facilities industry's average forecast revenue growth rate of 4.11%, and it is also forecast to beat the US market's average forecast revenue growth rate of 15.44%.
Starling Oncology's revenue in 2026 is $587,244,000.On average, 6 Wall Street analysts forecast STLN's revenue for 2026 to be $67,107,685,083, with the lowest STLN revenue forecast at $63,981,917,836, and the highest STLN revenue forecast at $71,752,002,443. On average, 5 Wall Street analysts forecast STLN's revenue for 2027 to be $84,971,541,720, with the lowest STLN revenue forecast at $77,610,140,734, and the highest STLN revenue forecast at $93,121,773,437.
In 2028, STLN is forecast to generate $112,107,726,500 in revenue, with the lowest revenue forecast at $108,744,494,705 and the highest revenue forecast at $116,490,119,445.